Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

18. März 2022 06:40 ET | Quelle: ORPHAZYME A/S

Notice of in-court restructuring proceedings of Orphazyme A/S

Orphazyme A/SCompany announcementNo. 11/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 18, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...
10. März 2022 16:05 ET | Quelle: ORPHAZYME A/S

Commencement of in-court restructuring of Orphazyme A/S

Orphazyme A/SCompany announcementNo. 10/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Will institute a reduction of approximately 50% of current work forceIntends to...
03. März 2022 03:35 ET | Quelle: ORPHAZYME A/S

Updated Financial Calender for 2022

Orphazyme A/SCompany announcementNo. 09/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 3, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...
28. Februar 2022 02:25 ET | Quelle: ORPHAZYME A/S

Anders Vadsholt takes over as CEO of Orphazyme

Company announcementNo. 08/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 28, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...
23. Februar 2022 16:05 ET | Quelle: ORPHAZYME A/S

Orphazyme announces update on regulatory review of arimoclomol in the European Union

Orphazyme A/SCompany announcementNo. 07/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 23, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US))...
18. Februar 2022 16:01 ET | Quelle: ORPHAZYME A/S

Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program

Orphazyme A/SCompany announcementNo. 06/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 18, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a...
15. Februar 2022 12:15 ET | Quelle: ORPHAZYME A/S

Resolutions passed at the Extraordinary General Meeting

Orphazyme A/SCompany announcementNo. 05/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 15, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the...
14. Februar 2022 16:01 ET | Quelle: ORPHAZYME A/S

Amendment of proposals put forward at the Extraordinary General Meeting

Orphazyme A/SCompany announcementNo. 04/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 14, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the...
11. Februar 2022 01:50 ET | Quelle: ORPHAZYME A/S

Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United States

Orphazyme A/SInvestor newsNo. 02/2022www.orphazyme.comCompany Registration No. 32266355 Orphazyme has made progress towards resubmission of the NDA for arimoclomol to the FDA and plans to request a...
07. Februar 2022 06:22 ET | Quelle: ORPHAZYME A/S

Orphazyme to present additional data on arimoclomol’s mechanism of action during 2022 Annual WORLDSymposium™

Orphazyme A/SInvestor NewsNo. 01/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 7, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...

Vorherige Seite

Nächste Seite